Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.0000 (0.17%) ($5.9200 - $6.1400) on Fri. Jul. 12, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.23% (three month average) | RSI | 68 | Latest Price | $6.0000(0.17%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS advances 1.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(10%) LQD(6%) VCIT(6%) SHY(5%) JETS(4%) | Factors Impacting ADMS price | ADMS will decline at least -1.615% in a week (0% probabilities). INDA(-8%) BNDX(-7%) XLE(-6%) USO(-6%) URA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.615% (StdDev 3.23%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.96(0.67%) | 10 Day Moving Average | $5.99(0.17%) | 20 Day Moving Average | $5.72(4.9%) | To recent high | -8.8% | To recent low | 18.8% | Market Cap | $170m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |